benzinga.com

Salubris Shifts Toward Innovative Cardiovascular Drugs as Generics Shrink

Shenzhen Salubris Pharmaceuticals logoShenzhen Salubris Pharmaceuticals
Sig2.04Sen+3.10Env0.00Soc0.00Gov+0.63

Salubris is accelerating its shift from generics as price cuts and expiring patents weigh on the category. From 2023 to 2025, generics fell from 48.8% to 30% of pharmaceutical sales while spending to launch new products rose sharply. Annual revenue climbed to 4.35 billion yuan in 2025, and first-half 2026 revenue grew 16.3% to 2.48 billion yuan, with net profit around 390 million yuan.

Coverage (2)

ABOUT

What is Fimmer?

Most feeds treat all company headlines the same. An executive interview, an office closure, stock analysis, and a data breach can sit side by side with no sense of scale. Fimmer ranks coverage by what matters, so important events stand out and signals are prioritised over noise. We cluster related company news and score each story using a range of metrics, so you see the most crucial stories first.

SCORING

What do the scores mean?

Significance (0–10) measures the scale of the real-world impact. Sentiment and ESG (−10 to +10) indicate the tone of the coverage and whether the change relates to environmental, social, or governance factors. Together, these scores help distinguish meaningful developments from routine company news. More information about our scoring methodology can be found on our About page.

DISCOVERY

Explore more on Fimmer

Search more than 10,000 public companies, browse the company index, explore their scores, and read the coverage behind them, with our core features available to everyone for free.

For more advanced features, Pro gives you access to dynamic feeds, custom sorting, and more ways to track the companies that matter to you.

More with Pro